Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Actual Status of Inhibitor Hemophilia Management in Russia

Nadezhda Zozulya, MD PhD, Tatiana Andreeva, MD PhD, Vladimir Vdovin, Farida Perina, Elena N. Parovichnikova, MD PhD, Valeri Savchenko, MD PhD Prof.

Blood (2015) 126 (23): 5579.

https://doi.org/10.1182/blood.V126.23.5579.5579

Published: 2015

Journal Articles

Safety and Efficiency of New Nonacog Alfa Drug in the Treatment of Bleeding Episodes in Patients with Severe and Moderate Hemophilia B

Igor Davydkin, Prof., Tatiana Andreeva, MD PhD, Vladimir Yu. Zorenko, MD PhD Prof., Valeria Konstantinova, MD PhD, Olga Zalepukhina, MD, Nina Klimova, MD, Georgy Mishin, MD, Igor Kurtov, MD PhD, Maria Shamina, MD PhD, Elena Fatenkova, MD, Olga Gusyakova, MD PhD, Alexandr Shuster, Academician, PhD, Dmitry Kudlay, MD PhD Prof., Sergey Lukyanov, MD PhD, Anton Borozinets, MD PhD, Eugene Nikitin, MD PhD, Ekaterina Klykova, MD PhD

Blood (2015) 126 (23): 4690.

https://doi.org/10.1182/blood.V126.23.4690.4690

Published: 2015

Journal Articles

Safety and Efficacy of New Moroctocog Alfa Drug (Octofactor) in Prophylactic Treatment in Adolescent Patients with Severe and Moderate Hemophilia a

Ekaterina Shiller, MD, Vladimir Vdovin, MD, Victor Petrov, MD PhD, Pavel Svirin, MD, Tatiana Andreeva, MD PhD, Inna Lavrichenko, MD, Artem Bullikh, MD, Igor Koltunov, MD PhD, Igor Davydkin, Prof., Igor Kurtov, MD PhD, Alexandr Shuster, Academician, PhD, Dmitry Kudlay, MD PhD Prof., Sergey Lukyanov, MD PhD, Anton Borozinets, MD PhD, Eugene Nikitin, MD PhD, Ekaterina Klykova, MD PhD

Blood (2015) 126 (23): 4703.

https://doi.org/10.1182/blood.V126.23.4703.4703

Published: 2015

Journal Articles

Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B

Tatiana Andreeva, MD PhD, Vladimir Yu. Zorenko, MD PhD Prof., Igor Davydkin, Prof., Valeria Konstantinova, MD PhD, Olga Zalepukhina, MD, Nina Klimova, MD, Georgy Mishin, MD, Igor Kurtov, MD PhD, Maria Shamina, MD PhD, Elena Fatenkova, MD, Olga Gusyakova, MD PhD, Alexandr Shuster, Academician, PhD, Dmitry Kudlay, MD PhD Prof., Sergey Lukyanov, MD PhD, Anton Borozinets, MD PhD, Eugene Nikitin, MD PhD, Ekaterina Klykova, MD PhD

Blood (2015) 126 (23): 3532.

https://doi.org/10.1182/blood.V126.23.3532.3532

Published: 2015

Journal Articles

Pharmacokinetics, Efficacy and Safety Of a Recombinant Factor IX (BAX326) In Previously-Treated Pediatric Patients < 12 Years Of Age With Severe Or Moderately Severe Hemophilia B

Tomasz Urasinski, Oleksandra Stasyshyn, Tatiana Andreeva, Luminita Rusen, Farida Perina, MyungShin Oh, Miranda Chapman, Borislava G Pavlova, Wing Yen Wong, Brigitt E. Abbuehl

Blood (2013) 122 (21): 1118.

https://doi.org/10.1182/blood.V122.21.1118.1118

Published: 2013

NARROW

Actual Status of Inhibitor Hemophilia Management in Russia

Safety and Efficiency of New Nonacog Alfa Drug in the Treatment of Bleeding Episodes in Patients with Severe and Moderate Hemophilia B

Safety and Efficacy of New Moroctocog Alfa Drug (Octofactor) in Prophylactic Treatment in Adolescent Patients with Severe and Moderate Hemophilia a

Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B

Pharmacokinetics, Efficacy and Safety Of a Recombinant Factor IX (BAX326) In Previously-Treated Pediatric Patients < 12 Years Of Age With Severe Or Moderately Severe Hemophilia B

Email alerts

ASH Publications

American Society of Hematology

Actual Status of Inhibitor Hemophilia Management in Russia

Safety and Efficiency of New Nonacog Alfa Drug in the Treatment of Bleeding Episodes in Patients with Severe and Moderate Hemophilia B

Safety and Efficacy of New Moroctocog Alfa Drug (Octofactor) in Prophylactic Treatment in Adolescent Patients with Severe and Moderate Hemophilia a

Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B

Pharmacokinetics, Efficacy and Safety Of a Recombinant Factor IX (BAX326) In Previously-Treated Pediatric Patients < 12 Years Of Age With Severe Or Moderately Severe Hemophilia B

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only